Janux Therapeutics Inc

NASDAQ JANX

Data sourced from

and

Daily

Download Data

Janux Therapeutics Inc Price to Book Ratio (P/B) on June 03, 2024: 4.35

Janux Therapeutics Inc Price to Book Ratio (P/B) is 4.35 on June 03, 2024, a 132.09% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Janux Therapeutics Inc 52-week high Price to Book Ratio (P/B) is 9.40 on May 02, 2024, which is 116.24% above the current Price to Book Ratio (P/B).
Janux Therapeutics Inc 52-week low Price to Book Ratio (P/B) is 0.70 on November 09, 2023, which is -83.87% below the current Price to Book Ratio (P/B).
Janux Therapeutics Inc average Price to Book Ratio (P/B) for the last 52 weeks is 2.54.

NASDAQ: JANX

Janux Therapeutics Inc

CEO	Dr. David Alan Campbell Ph.D.
IPO Date	June 11, 2021
Location	United States
Headquarters	11099 North Torrey Pines Road, La Jolla, CA, United States, 92037
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Key trends